The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
📉 Microsoft Q1 2026 Earnings: Strong Numbers Mask Investor Anxiety Over AI Spending
🚀 Alphabet Soars on AI-Driven Results, Shares Rally 7% in After-Hours Trading
Meta drops 8% despite strong revenue growth 🔎
Upcoming Meta earnings: will the AI transformation be well received by the market? 🔎